<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In human Burkitt's <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) BRG cells, a t(8;14) translocation, placing c-myc near the Emu enhancer of the H chain locus, causes <z:e sem="disease" ids="C1519678" disease_type="Neoplastic Process" abbrv="">tumor expansion</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Earlier, we showed that a <z:chebi fb="0" ids="48021">peptide nucleic acid</z:chebi> complementary to the Emu sequence (PNAEmu), specifically inhibited the expression of translocated c-myc and impaired the growth of BRG cells-induced subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in mice suffering from <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> (<z:mp ids='MP_0002536'>SCID</z:mp>) </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, the therapeutic potential of PNAEmu was evaluated in a systemic mouse model </plain></SENT>
<SENT sid="3" pm="."><plain>BRG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells transfected with the luciferase gene were inoculated intravenously into <z:mp ids='MP_0002536'>SCID</z:mp> mice resulting in a preferential expansion, similar to the one of human adult patients, in the abdominal cavity, central <z:mp ids='MP_0008912'>nervous</z:mp> system and bone marrow </plain></SENT>
<SENT sid="4" pm="."><plain>The mice were chronically injected intraperitoneally either with PNAEmu or with control <z:chebi fb="3" ids="48021">PNA</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The treatment was stopped when the control animals developed severe neurological symptoms </plain></SENT>
<SENT sid="6" pm="."><plain>As detected both by inspection at necropsy and imaging, overall <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in PNAEmu-treated mice decreased by &gt;80% </plain></SENT>
<SENT sid="7" pm="."><plain>Histological and immunohistochemical studies showed, only in PNAEmu-treated mice, a substantially reduced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell growth at the major sites of invasion and vast areas of <z:mp ids='MP_0001651'>necrosis</z:mp> in the lymphomatous tissues, with concomitant c-myc expression downregulation </plain></SENT>
<SENT sid="8" pm="."><plain>Altogether, the data support the therapeutic potential of PNAEmu in human adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>